Serine/threonine-protein kinase receptor R3 is an
enzyme that in humans is encoded by the ACVRL1gene.[5][6][7]
ACVRL1 is a receptor in the
TGF beta signaling pathway. It is also known as activin receptor-like kinase 1, or ALK1.
Function
This gene encodes a type I cell-surface receptor for the TGF-beta superfamily of ligands. It shares with other type I receptors a high degree of similarity in serine-threonine kinase subdomains, a glycine- and serine-rich region (called the GS domain) preceding the kinase domain, and a short C-terminal tail. The encoded protein, sometimes termed ALK1, shares similar domain structures with other closely related ALK or activin receptor-like kinase proteins that form a subfamily of receptor serine/threonine kinases. Mutations in this gene are associated with hereditary hemorrhagic telangiectasia (HHT) type 2, also known as Rendu-Osler-Weber syndrome 2.[7]
^Vandenbriele C, Peerlinck K, de Ravel T, Verhamme P, Vanassche T (April 2014). "Pulmonary arterio-venous malformations in a patient with a novel mutation in exon 10 of the ACVRL1 gene". Acta Clinica Belgica. 69 (2): 139–41.
doi:
10.1179/0001551213Z.00000000012.
PMID24724759.
S2CID35264961.
^Jones G, Robertson L, Harrison R, Ridout C, Vasudevan P (August 2014). "Somatic mosaicism in ACVRL1 with transmission to several offspring affected with severe pulmonary arterial hypertension". American Journal of Medical Genetics. Part A. 164A (8): 2121–3.
doi:
10.1002/ajmg.a.36568.
PMID24753439.
S2CID5417225.
^Laping NJ, Grygielko E, Mathur A, Butter S, Bomberger J, Tweed C, Martin W, Fornwald J, Lehr R, Harling J, Gaster L, Callahan JF, Olson BA (July 2002). "Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542". Molecular Pharmacology. 62 (1): 58–64.
doi:
10.1124/mol.62.1.58.
PMID12065755.
S2CID792324.
Further reading
Attisano L, Cárcamo J, Ventura F, Weis FM, Massagué J, Wrana JL (November 1993). "Identification of human activin and TGF beta type I receptors that form heteromeric kinase complexes with type II receptors". Cell. 75 (4): 671–80.
doi:
10.1016/0092-8674(93)90488-C.
PMID8242742.
S2CID25408172.
Kjeldsen AD, Brusgaard K, Poulsen L, Kruse T, Rasmussen K, Green A, Vase P (February 2001). "Mutations in the ALK-1 gene and the phenotype of hereditary hemorrhagic telangiectasia in two large Danish families". American Journal of Medical Genetics. 98 (4): 298–302.
doi:
10.1002/1096-8628(20010201)98:4<298::AID-AJMG1093>3.0.CO;2-K.
PMID11170071.
Serine/threonine-protein kinase receptor R3 is an
enzyme that in humans is encoded by the ACVRL1gene.[5][6][7]
ACVRL1 is a receptor in the
TGF beta signaling pathway. It is also known as activin receptor-like kinase 1, or ALK1.
Function
This gene encodes a type I cell-surface receptor for the TGF-beta superfamily of ligands. It shares with other type I receptors a high degree of similarity in serine-threonine kinase subdomains, a glycine- and serine-rich region (called the GS domain) preceding the kinase domain, and a short C-terminal tail. The encoded protein, sometimes termed ALK1, shares similar domain structures with other closely related ALK or activin receptor-like kinase proteins that form a subfamily of receptor serine/threonine kinases. Mutations in this gene are associated with hereditary hemorrhagic telangiectasia (HHT) type 2, also known as Rendu-Osler-Weber syndrome 2.[7]
^Vandenbriele C, Peerlinck K, de Ravel T, Verhamme P, Vanassche T (April 2014). "Pulmonary arterio-venous malformations in a patient with a novel mutation in exon 10 of the ACVRL1 gene". Acta Clinica Belgica. 69 (2): 139–41.
doi:
10.1179/0001551213Z.00000000012.
PMID24724759.
S2CID35264961.
^Jones G, Robertson L, Harrison R, Ridout C, Vasudevan P (August 2014). "Somatic mosaicism in ACVRL1 with transmission to several offspring affected with severe pulmonary arterial hypertension". American Journal of Medical Genetics. Part A. 164A (8): 2121–3.
doi:
10.1002/ajmg.a.36568.
PMID24753439.
S2CID5417225.
^Laping NJ, Grygielko E, Mathur A, Butter S, Bomberger J, Tweed C, Martin W, Fornwald J, Lehr R, Harling J, Gaster L, Callahan JF, Olson BA (July 2002). "Inhibition of transforming growth factor (TGF)-beta1-induced extracellular matrix with a novel inhibitor of the TGF-beta type I receptor kinase activity: SB-431542". Molecular Pharmacology. 62 (1): 58–64.
doi:
10.1124/mol.62.1.58.
PMID12065755.
S2CID792324.
Further reading
Attisano L, Cárcamo J, Ventura F, Weis FM, Massagué J, Wrana JL (November 1993). "Identification of human activin and TGF beta type I receptors that form heteromeric kinase complexes with type II receptors". Cell. 75 (4): 671–80.
doi:
10.1016/0092-8674(93)90488-C.
PMID8242742.
S2CID25408172.
Kjeldsen AD, Brusgaard K, Poulsen L, Kruse T, Rasmussen K, Green A, Vase P (February 2001). "Mutations in the ALK-1 gene and the phenotype of hereditary hemorrhagic telangiectasia in two large Danish families". American Journal of Medical Genetics. 98 (4): 298–302.
doi:
10.1002/1096-8628(20010201)98:4<298::AID-AJMG1093>3.0.CO;2-K.
PMID11170071.